Gastroenterohepatology Department, İstanbul Faculty of Medicine, İstanbul University, İstanbul 34093, Turkey.
Gastroenterohepatology Department, Medical Faculty, Yeditepe University, İstanbul 34755, Turkey.
Exp Oncol. 2020 Sep;42(3):208-214. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-3.15125.
Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC.
We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC.
60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits.
All patients had cirrhosis, and the Child - Pugh stages were as follows: 61.5% Child - Pugh A, 35.9% Child - Pugh B and 2.6% Child - Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05).
IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients.
肝细胞癌（HCC）是全球日益严重的问题。确定预后对于 HCC 的治疗管理非常重要。
我们旨在研究白细胞介素（IL）-29、半乳糖凝集素-3、瘦素、纤维连接蛋白和蛋白酶激活受体-1 对 HCC 患者的预后和诊断的影响。
这项前瞻性研究纳入了 60 名 HCC 患者（75%为男性）和 20 名健康志愿者（70%为男性）。在接受任何辅助或转移性治疗之前，在首次入院期间采集血清样本。使用 ELISA 试剂盒测定血清生物标志物。
所有患者均患有肝硬化，Child-Pugh 分期如下：61.5%为 Child-Pugh A 级，35.9%为 Child-Pugh B 级，2.6%为 Child-Pugh C 级（61.7%为乙型肝炎病毒，11.7%为丙型肝炎病毒，6.7%为乙型肝炎病毒+丙型肝炎病毒，11.7%为酒精性，8.3%为不明原因）。53%的 HCC 患者在中位 7.5 个月内死亡。HCC 患者的 IL-29 血清水平平均值高于对照组（32.55 pg/ml 比 11.46 pg/ml，p<0.015）。半乳糖凝集素-3 水平在 HCC 组中显著升高（6.7 ng/ml 比 1.38 ng/ml，p<0.001）。纤维连接蛋白水平在对照组中高于 HCC 组（260635 ng/ml 比 257353 ng/ml）。然而，两组之间的蛋白酶激活受体-1 和瘦素水平平均值相似（p>0.05）。根据中位数将生物标志物分为两组。在对数秩分析中，生物标志物对生存无影响（p>0.05）。
HCC 患者的 IL-29 和半乳糖凝集素-3 水平显著升高。虽然 IL-29 和半乳糖凝集素-3 可作为 HCC 的诊断标志物，但它们对 HCC 患者无预后价值。
